REVIEW ARTICLE
Figure from article: Immunohistochemistry in...
 
KEYWORDS
TOPICS
ABSTRACT
Although the clinical background, gross and hematoxylin-eosin examination usually suffice for the placental diagnosis, immunohistochemistry (IHC) is essential in many cases, particularly in high-risk pregnancy. The double E-cadherin/CD34 immuno-stain is the backbone of it, particularly for diagnosing the early fetal vascular malper-fusion (FVM) characterized by the endothelial fragmentation preceding the villous hypovascularity/avascularity of distal FVM. The stain is 3–4 times more sensitive than the stromal vascular karyorrhexis, the other early FVM lesion. The endothelial fragmentation may help in timing FVM and its grading as well as in revealing its temporal heterogeneity. The immunostain makes the FVM the most common pattern of placental injury in the population of pregnancies dominated by mass-forming fetal anomalies. The immunostain is also useful in diagnosing villous hypomaturity by highlighting widened vasculosyncytial membranes. Of other immunostains, cyto-keratin IHC is invaluable for confirmation of intrauterine pregnancy in chorionic villi-negative uterine curettings. Cytokeratin and smooth muscle actin are valuable in borderline cases of shallow placental implantation. P57 immunostain is invaluable for the diagnosis of early complete hydatidiform moles. Finally, IHC may be decisive in diagnosing viral placentitis, particularly cytomegaloviral, herpetic and parvoviral.
REFERENCES (53)
1.
Roberts DJ, Polizzano C. Atlas of placental pathology. American Registry of Pathology, Arlington, Virginia 2021.
 
2.
Heerema-McKenney A, Popek EJ, DePaepe ME (eds). 2nd ed. Diagnostic pathology: placenta. Amirsys, Elsevier, Philadelphia 2019.
 
3.
Khong TY, Mooney EE, Nikkels PGJ, Morgan TK, Gordijn SJ (eds). Pathology of the placenta, Springer 2019, 83.
 
4.
Redline RW, Ravishankar S, Bagby CM, Saab ST, Zarei S. Four major patterns of placental injury: a stepwise guide for understanding and implementing the 2016 Amsterdam consensus. Modern Pathol 2021; 34: 1074-1092.
 
5.
Kim CF, Ravishankar S, Sybenga AB. Survival guide to placental pathology. Roberts D (ed.). The Innovative Science Press, Arlington, VA, USA 2026.
 
6.
Horn LC, Opitz S, Handzel R, Brambs CE. Histopathology and clinical aspects of extrauterine pregnancy. Pathologe 2018; 39: 431-444.
 
7.
Daya D, Sabet L. The use of cytokeratin as a sensitive and reliable marker for trophoblastic tissue. Am J Clin Pathol 199; 95: 137-141.
 
8.
Konoplev SN, Dimashkieh, HH, Stanek J. Cytokeratin immunohistochemistry: a procedure for exclusion of pregnancy in chorionic villi-negative specimen. Placenta 2004; 25: 146-152.
 
9.
Castro E, Tony Parks W, Galambos C. Neither normal nor diseased placentas contain lymphatic vessels. Placenta 2011; 32: 310-316.
 
10.
Wang Y, Sun J, Gu Y, Zhao S, Groome LJ, Alexander JS. D2- 40/podoplanin expression in human placenta. Placenta 2011; 32: 27-32.
 
11.
Faye-Petersen OM, Kapur RP. Placental mesenchymal dysplasia. Surg Pathol Clin 2013; 6: 127-151.
 
12.
Stanek J, Funk D. Clinicopathologic correlations and interdependence of basic patterns of placental injury. Virchows Arch 2025; 487: 1357-1370.
 
13.
Stanek J. Placental infectious villitis versus villitis of unknown etiology. Pol J Pathol 2017; 68: 55-65.
 
14.
Sampath V, Narendran V, Donovan EF, Stanek J, Schleiss MR. Nonimmune hydrops fetalis due to congenital cytomegalovirus infection in a premature infant. J Perinatol 2005; 25: 608-611.
 
15.
Bedolla G, Stanek J. Intrauterine hematogenous herpetic infection. Arch Pathol Lab Med 2004; 128: 1189-90.
 
16.
Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 2008; 61: 1184-1192.
 
17.
Li JJ, Henwood T, Hal SV, Charlton A. Parvovirus infection: an immunohistochemical study using fetal and placental tissue. Ped Dev Pathol 2025; 18: 30-39.
 
18.
Sharps MC, Hayes DJL, Lee S, Zou Z, Brady CA, Almoghrabi Y, et al. A structural review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection. Placenta 2020; 101: 13-29.
 
19.
Marton T, Hargitai B, Hunter K, Pugh M, Murray P. Massive perivillous fibrin deposition and chronic histiocytic intervillosits a complication of SARS-CoV-2 infection. Pediatr Dev Pathol 2021; 24: 450-454.
 
20.
Rosenberg AZ, Yu W, Hill DA, Reyes CA, Schwartz DA. Placental pathology of Zika virus: viral Infection of the placenta Induces villous stromal macrophage (Hofbauer cell) proliferation and hyperplasia. Arch Pathol Lab Med 2017; 141: 43-48.
 
21.
Kadyrov M, Kaufmann P, Huppertz B. Expression of a cytokeratin 18 neo-epitope is a specific marker for trophoblast apoptosis in human placenta. Placenta 2001; 22: 44-48.
 
22.
Stanek J. Hypoxic patterns of placental injury: a review. Arch Pathol Lab Med 2013; 137: 706-720.
 
23.
Stanek J, Al-Ahmadie H. Laminar necrosis of placental membranes: a histologic sign of uteroplacental hypoxia. Pediatr Dev Pathol 2005; 8: 34-42.
 
24.
Stanek J. Membrane microscopic chorionic pseudocysts are associated with increased amount of placental extravillous trophoblasts. Pathology 2010; 42: 125-130.
 
25.
Stanek J. Diagnosing placental membrane hypoxic lesions increases the sensitivity of placental examination. Arch Pathol Lab Med 2010; 134: 989-995.
 
26.
Mutema G, Stanek J. Numerical criteria for the diagnosis of placental chorangiosis using CD34 immunostaining. Trophoblast Res 1999; 13: 443-452.
 
27.
Stanek J. Chorangiosis of chorionic villi: what does it really mean? Arch Pathol Lab Med 2016; 140: 588-593.
 
28.
Kingdom JC, Kaufmann P. Oxygen and placental villous development: origins of fetal hypoxia. Placenta 1997; 18: 613-621.
 
29.
Ferreira EO, Stefanovici C, Kostadinov S, Duncan V. Umbilical cord hemangiomas: a multi-institutional case series with literature review. Pediatr Dev Pathol 2024; 27: 569-575.
 
30.
Khong TY, Mooney EE, Ariel I, Balmus NCM, Boyd TK, Brundler MA, et al. Sampling and definitions of placental lesions. Amsterdam placental workshop group consensus statement. Arch Pathol Lab Med 2016; 140: 698-713.
 
31.
Stanek J. E-cadherin/CD34 double immunostain in placental diagnosis. Pol J Pathol 2024; 75: 171-181.
 
32.
Higgins M, McAuliffe FM, Mooney EE. Clinical associations with a placental diagnosis of delayed villous maturation: a retrospective study. Pediatr Dev Pathol 2011; 14: 273-279.
 
33.
Stanek J. Shallow placentation: A distinct category of placental lesions. Am J Perinatol 2023; 40: 1328-1335.
 
34.
Stanek J. Chorionic disc extravillous trophoblasts in placental diagnosis. Am J Clin Pathol 2011; 136: 540-547.
 
35.
Stanek J, Weng E. Microscopic chorionic pseudocysts in placental membranes: a histologic lesion of in utero hypoxia. Pediatr Dev Pathol 2007; 10: 192-198.
 
36.
Bonanni G, Lopez-Giron MC, Allen L, Fox K, Silver RM, Hobson SR, et al. Guidelines on placenta accreta spectrum disorders; a systematic review. Obstet Gynaecol Surv 2026; 81: 10-12.
 
37.
Stanek J. Placenta creta: a spectrum of lesions associated with shallow placental implantation. Obstet Gynecol Int 2020; 2020: 4230451.
 
38.
Stanek J, Drummond Z. Occult placenta accreta: the missing link in the diagnosis of abnormal placentation. Pediatr Dev Pathol 2007; 10: 266-262.
 
39.
Stanek J, Eis ALW, Myatt L. Nitrotyrosine immunostaining correlates with increased extracellular matrix: evidence of postplacental hypoxia. Placenta 2001; 22: S56-S62.
 
40.
Stanek J. Fetal vascular malperfusion. Arch Pathol Lab Med 2018; 142: 679-680.
 
41.
Stanek J, Abdaljaleel M. CD34 immunostain increases the sensitivity of placental diagnosis of fetal vascular malperfusion in stillbirth. Placenta 2019; 77: 30-38.
 
42.
Pinar H, Carpenter M. Placenta and umbilical cord abnormalities seen with stillbirth. Clin Obstet Gynecol 2010; 53: 656-672.
 
43.
Stanek J. Clinical significance of the large fetal vessel lesions in placental fetal vascular malperfusion. Lab Invest 2024; 104: 102089.
 
44.
Stanek J. Distal villous lesions are clinically more relevant than proximal large muscular vessel lesions of placental fetal vascular malperfusion. Histol Histopathol 2022; 37: 365-372.
 
45.
Stanek J, Drach A. Placental CD34 immunohistochemistry in fetal vascular malperfusion in stillbirth. J Obstet Gynaecol Res 2022; 48: 719-728.
 
46.
Stanek J. Placental recent/on-going foetal vascular malperfusion with endothelial fragmentation is diagnostically equivalent to established distal villous lesions of foetal vascular malperfusion. Pol J Pathol 2022; 73: 198-207.
 
47.
Stanek J. Temporal heterogeneity of placental segmental fetal vascular malperfusion: timing but not etiopathogenesis. Virchows Arch 2021; 478: 905-9214.
 
48.
Stanek J. Timing of histological distal villous fetal vascular malperfusion in the placenta: clinical significance and placental features. Ann Clin Lab Sci 2024; 54: 289-298.
 
49.
Stanek J. CD34 immunostain increases the sensitivity of placental examination for distal villous vascular malperfusion in livebortn infants. Placenta 2023; 140: 117-124.
 
50.
Stanek J. Grading fetal vascular malperfusion and short-term perinatal outcome. Pol J Pathol 2020; 71: 291-300.
 
51.
Stanek J. Segmental villous mineralization: a placental feature of fetal vascular malperfusion. Placenta 2019; 86: 20-27.
 
52.
Genest DR. Estimating the time of death in stillborn foetuses: II. Histologic evaluation of the placenta; a study of 71 stillborns. Obstet Gynecol 1992; 80: 585-592.
 
53.
Stanek J. Placental fetal vascular malperfusion in maternal diabetes mellitus. J Perinat Med 2024; 53: 179-187.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top